research support from: Actelion Pharmaceuticals US, Bayer AG, Bristol-Myers Squibb, Inventiva, Medac, Pfizer Inc, Roche Pharmaceuticals, Genentech and Biogen IDEC Inc. Sanofi-Aventis Pharmaceutical, Servier, Consultant for: Actelion Pharmaceuticals US, Bayer AG, Bristol-Myers Squibb, Inventiva, Medac, Pfizer Inc, Roche Pharmaceuticals, Genentech and Biogen IDEC Inc., Sanofi-Aventis Pharmaceutical, M. Matucci-Cerinic Grant/research support from: Pfizer, Bristol-Myers Squibb, Actelion, UCB Pharma, Consultant for: Actelion, Bayer, ChemomAb, Genentech/Roche, Inventiva, Lilly, Pfizer, J. Pope Grant/research support from: Actelion, Bayer AG, Bristol-Myers Squibb, Merck, Pfizer Inc, Roche, Consultant for: Actelion, Bayer AG, Bristol-Myers Squibb, Merck, Pfizer Inc, Roche, C. Denton Consultant for: Actelion Pharmaceuticals US, Bayer AG, GlaxoSmithKline, CSL Behring, Merck-Serono, Roche Pharmaceuticals, Genentech and Biogen IDEC Inc., Inventiva, Sanofi-Aventis Pharmaceutical, Boehringer Ingelheim, Speakers bureau: Actelion Pharmaceuticals US, Bayer AG, GlaxoSmithKline, CSL Behring, Merck-Serono, Roche Pharmaceuticals, Genentech and Biogen IDEC Inc., Inventiva, Sanofi-Aventis Pharmaceutical, Boehringer Ingelheim, D. Khanna Shareholder of: Eicos, Grant/research support from: Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Genentech/Roche, NIH, Pfizer, Sanofi-Aventis Pharmaceuticals, Consultant for: Actelion Pharmaceuticals US, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Chemomab, Corbus, Covis, Cytori, Eicos, EMD Serono, Genentech/Roche, Pfizer, Gilead, GlaxoSmithKline, Sanofi-Aventis Pharmaceuticals, and UCB Pharma, O. Distler Grant/research support from: Actelion, Bayer, Biogen Idec, Boehringer Ingelheim, ChemomAb, EspeRare Foundation, Genentech/Roche, GlaxoSmithKline, Inventiva, Lilly, Medac, Medimmune, Mitsubishi Tanabe Pharma, Pharmacyclics, Novartis, Pfizer, Sanofi, Sinoxa, and UCB in the area of potential treatments of scleroderma and its complications. Patent mir-29 for the treatment of systemic sclerosis licensed, Consultant for: Actelion, Bayer, Biogen Idec, Boehringer Ingelheim, ChemomAb, EspeRare Foundation, Genentech/Roche, GlaxoSmithKline, Inventiva, Lilly, Medac, Medimmune, Mitsubishi Tanabe Pharma, Pharmacyclics, Novartis, Pfizer, Sanofi, Sinoxa, and UCB in the area of potential treatments of scleroderma and its complications.

DOI: 10.1136/annrheumdis-2018-eular.5248

SAT0514

MRI – GUIDED THERAPY FOR SYSTEMIC SCLEROSIS ASSOCIATED MYOSITIS

Y. Braun-Moscovici¹, D. Militianu², N. Puchkov³, D. Markovits¹, M. Braun³, M. A. Nahir¹, A. Balbir-Gurman¹. ¹Rheumatology department, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion; ²Department of Medical Imaging, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion, Haifa; ³Liver Institute, Beilinson Hospital, Sackler School of Medicine, Tel Aviv University, Petach Tikva, Israel

Background: Muscle involvement in systemic sclerosis (SSc) has a significant impact on morbidity, functional capacity, and mortality. The muscle histopathology is heterogeneous including inflammatory and fibrotic changes. Currently there are no satisfactory means to diagnose inflammatory myopathy in SSc pts with normal creatine kinase (CK) and to assess the response to therapy.

Objectives: Our aim was to evaluate whether muscle magnetic resonance imaging (MRI) might be a tool to diagnose inflammatory myopathy in SSc patients (pts) and to assess the effect of muscle oriented- immunomodulatory therapy.

Methods: We retrospectively analysed the clinical data of 290 consecutive SSc pts seen at our centre between the years 2012–2017. Our cohort is part of the EUSTAR registry (centre 042). Pts with muscle weakness as defined by the Medsger muscle severity score of ≥ 1 and at least one MRI study were included. Clinical data analysis included SSc subtype, disease duration, modified Rodnan skin score (mRSS), Medsger muscle severity score, CK, autoantibody profile, MRI and immunomodulatory treatment.

Results: 26 pts with muscle weakness answered the criteria of Medsger muscle severity score of ≥ 1 MRI data were available, in 17 of the pts. Muscle oedema and fasciitis were seen in MRI in 13 pts (10 diffuse subset, median: age 40, disease duration 1.25 years, mRSS 13.5). MRI was normal in 4 pts (2 diffuse SSc, median: age 50 years, disease duration 6 years, mRSS 4). CK was normal in 10 pts with pathologic MRI. Anti-topoisomerase was positive in 6 pts, RNA polymerase 3 – in 3 pts, anti-centromere – in 2 pts and 6 pts were only ANA positive. Muscle biopsy results were available in 4 pts: Biopsy was compatible with myositis in 3 pts with pathologic MRI and revealed fibrosis in 1 pt with normal MRI. 14 pts received immunomodulatory treatment: rituximab (3 pts), rituximab and intravenous immunoglobulins (IVIG) (3 pts), IVIG and methotrexate/azathioprine/mycophenolate mofetil.⁸ A second MRI was performed in 6 pts with first pathologic MRI, after 12 months of treatment. Significant regression of muscle oedema and per fasciitis was observed in 5 pts and correlated with clinical amelioration, with improvement of muscle strength. No clinical and imaging improvement occurred in one patient, despite the treatment. No change in muscle strength was seen in the patient with normal MRI and evidence of fibrosis on muscle biopsy, although the skin score improved.

Conclusions: MRI might serve as a non-invasive tool for diagnosis of inflammatory myopathy in SSc pts with early disease, Medsger muscle severity score of ≥ 1 and normal CK and for assessment of treatment efficacy.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.6511

SAT0515

CLINICAL CHARACTERISTICS OF PATIENTS WITH CANCER-ASSOCIATED MYOSITIS COMPLICATED BY INTERSTITIAL LUNG DISEASE

Y. Kaneko¹, T. Nunokawa², Y. Taniguchi³, Y. Yamaguchi⁴, T. Gono⁵, K. Masui⁶, A. Kawakami⁷, Y. Kawaguchi⁸, S. Sato⁹, M. Kuwana¹⁰ on behalf of JAMI investigators. ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine; ²Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo; ³Department of Endocrinology, Metabolism, Nephrology and Rheumatology, Kochi Medical School Hospital, Kochi; ⁴Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Kanagawa; ⁵Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo; ⁶Department of Anesthesiology, National Defense Medical College School of Medicine, Saitama; ⁷Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki; ⁸Institute of Rheumatology, Tokyo Women's Medical University, Tokyo; ⁹Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Kanagawa, Japan

Background: Cancer-associated myositis (CAM) is believed to be rarely complicated by interstitial lung disease (ILD), and, thus, detailed clinical characteristics of CAM in patients with polymyositis (PM)/dermatomyositis (DM)-associated ILD are not well known.

Objectives: To clarify the incidence, risk factors, and impact on survival of malignancy in patients with PM/DM-associated ILD, using a large cohort data.

Methods: We used 497 patients with PM/DM-associated ILD enrolled in a multi-centre retrospective cohort of incident cases from 44 institutions across Japan (JAMI). CAM was defined as malignancy diagnosed within 3 years before or after PM/DM diagnosis. Demographic data and clinical characteristics were recorded at the time of diagnosis, and follow-up survival and malignancy data were collected prospectively.

Results: Thirty-two patients with CAM (6.4%) were identified. Patients in the CAM group were older (64.3 vs 55.1 years, $p < 0.001$), had shorter disease duration at onset (4.1 vs 7.0 months, $p = 0.01$), and presented with arthritis less frequently (24.1 vs 48.5%, $p = 0.01$), in comparison with those with non-CAM group. All patients with CAM were older than 40 years, and the proportion of CAM increased along with the age. Patients who were ≥ 59 years at diagnosis and lacked arthritis were at 12 times higher risk for concomitant malignancy than those without such features (figure 1). Frequencies of autoantibodies, including anti-MDA5, anti-ARS, and anti-TIF1gamma, were not different between the groups. In 19 patients (59%), malignancy was diagnosed within 3 months before or after PM/DM diagnosis. Eleven CAM patients were died, and cause of deaths included ILD in 6 and malignancy in 5. Survival analysis by Kaplan-Meier method demonstrated that CAM patients had a poorer survival than did non-CAM patients ($p = 0.016$).

Conclusions: In patients with PM/DM-associated ILD, older age at diagnosis and lack of arthritis are predictors for concomitant malignancy, which leads to a reduced survival.

Disclosure of Interest: Y. Kaneko Speakers bureau: Astellas, T. Nunokawa: None declared, Y. Taniguchi: None declared, Y. Yamaguchi: None declared, T. Gono: None declared, K. Masui: None declared, A. Kawakami: None declared, Y. Kawaguchi: None declared, S. Sato Grant/research support from: a patent on anti-MDA5 antibody-measuring kit, M. Kuwana Grant/research support from: Astellas, Speakers bureau: Astellas, Japan Blood Products Organisation, Medical and Biological Laboratories

DOI: 10.1136/annrheumdis-2018-eular.3601

SATURDAY, 16 JUNE 2018

Vasculitis

SAT0516

TWO DISTINCT SUBSETS OF LOW DENSITY GRANULOCYTES IN ANCA ASSOCIATED VASCULITIS

A. Endo, Y. Komagata, K. Yamagishi, N. Ikegaya, K. Fukuoka, M. Karube, Y. Arimura, S. Kaname. Division of Nephrology and Rheumatology, First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan

Background: Low density granulocyte (LDG), a proinflammatory population of neutrophils, was first described in systemic lupus erythematosus (SLE) and has